You are here

Home » Content

Efficacy of Photodynamic Therapy Versus Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy

Kronik Santral Seröz Koryoretinopatide Fotodinamik Tedavinin ve İntravitreal Bevacizumab Enjeksiyonunun Etkinliği

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2014

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: To compare the efficacy of photodynamic therapy (PDT) versus intravitreal bevacizumab (IVB) injection for the treatment of chronic central serous chorioretinopathy (CSC). Method: The medical records of 16 eyes of 15 patients who received PDT (n=9) or IVB (n=6) for symptomatic chronic central serous chorioretinopathy (CSC) were retrospectively reviewed. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and subretinal fluid (SRF) volume were compared between the two patient groups at baseline and at 1,3 and 6 months after treatment. Results: Median BCVA was similar in both groups at all time points (p>0.05). The reduction of CMT was significant at the 1st and 3rd month (p<0.05), however, it was non-significant at the 6th month among two groups (p˃0.05). SRF resorption was significantly better in the PDT group when compared to IVB group at the 1st and 3rd month (p<0.05), while it was non-significant at the 6th month (p˃0.05). Conclusion: Both PDT and IVB injection provided visual and anatomical recovery for chronic CSC. However, PDT appeared superior to IVB in terms of improving CMT and SRF throughout three months after treatment.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Kronik santral seröz koryoretinopati (SSR) tedavisinde fotodinamik tedavi (PDT) ile intravitreal bevacizumab’ın (IVB) etkinliğini karşılaştırmak. Yöntem: Semptomatik kronik SSR nedeniyle PDT (n=9) veya IVB (n=6) uygulanmış 15 hastanın 16 gözüne ait dosyalar retrospektif olarak incelendi. İki grup, en iyi düzeltilmiş görme keskinliği (EDGK), santral makülar kalınlık (SMK) ve subretinal sıvı (SRS) volümü açısından tedavi sonrası 1., 3. ve 6. aylarda karşılaştırıldı. Bulgular: Tüm zaman dilimlerinde, ortanca EDGK açısından her iki grup benzerdi (p>0.05). SMK azalması açısından 1. ve 3. aylarda iki grup arasında anlamlı fark izlenirken (p<0.05), 6. ayda bu fark anlamlı değildi (p˃0.05). SRS rezorpsiyonu 1. ve 3. aylarda PDT grubunda anlamlı olarak daha iyi iken 6. ayda bu fark anlamlı değildi (p˃0.05). Sonuç: Hem PDT hem de IVB enjeksiyonu kronik CSC’de görsel ve anatomik düzelme sağlamaktadır. Ancak PDT, tedavi sonrası üç aylık dönemde SMK’de ve SRS’de düzelme açısından IVB’den üstün görünmekterdir.
FULL TEXT (PDF): 
PDF icon arastirmax-efficacy-photodynamic-therapy-versus-intravitreal-bevacizumab-injection-chronic-central-serous-chorioretinopathy.pdf
  • 1
1
6
  • English

REFERENCES

References: 

1. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126–145.
2. Lida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 1999; 19:.508–512.
3. Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 709–712.
4. Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992; 2: 103–114.
5. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997; 104: 616–622.
6. Parodi MB, Pozzo SD, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003; 23: 235–237.
7. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM Jr, Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of
Tufan HA ve ark. Photodynamic Therapy vs Intravitreal Bevacizumab
Abant Med J 2014;3(1):1-6 5
chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288–298.
8. Moon JW, Yu HG, Kim TW, Kim HC, Chung H. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1315–1323.
9. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009; 53:52–56.
10. Gregori-Gisbert I, Aguirre-Balsalobre F, García-Sánchez J, León-Salvatierra G, Mengual-Verdú E, Hueso-Abancéns JR Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection. Arch Soc Esp Oftalmol 2011; 86: 407-411.
11. Lim SJ, Roh MI, Kwon OW Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2009; 30: 100–106.
12. Torres-Soriano ME, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, Abraham-Marín M, Ober MD et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008; 246: 1235-1239.
13. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009; 19: 613-617.
14. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. – Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541–560.
15. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109: 1723–1725.
16. Caccavale A, Imparato M, Romanazzi F, Negri A, Porta A, Ferentini F. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses 2009; 73: 435-437.
17. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina 2011; 31: 766-771.
18. Piccolino CF, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752–763.
19. Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, Gómez-Ulla F. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 2010; 88: 371–376.
20. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006; 90: 869–874.
21. Shin JY, Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2010; 31: 119–126.
22. Niegel MF, Schrage NF, Christmann S, Degenring RF. Intravitreal bevacizumab for chronic central serous chorioretinopathy. Ophthalmology 2008; 105: 943-945.
23. Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012; 56: 608-612.

Thank you for copying data from http://www.arastirmax.com